Patent: 9,814,714
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 9,814,714
Title: | Kinase modulation, and indications therefor |
Abstract: | The present disclosure provides methods of treating a subject suffering from or at risk of a BRAF V600 mutation or BRAF fusion mutation related disease or condition, without activating the MAPK pathway or inducing expression of MAPK pathway genes in cells harboring wild-type BRAF. |
Inventor(s): | Ibrahim; Prabha N. (Mountain View, CA), Zhang; Chao (Moraga, CA), Spevak; Wayne (Berkeley, CA), Zhang; Jiazhong (Foster City, CA), Wu; Guoxian (Palo Alto, CA), Lin; Jack (Hercules, CA), Cho; Hanna (Oakland, CA), Nespi; Marika (Berkeley, CA), Shi; Songyuan (Fremont, CA), Ewing; Todd (Walnut Creek, CA), Zhang; Ying (Fremont, CA), Bollag; Gideon (Orinda, CA) |
Assignee: | Plexxikon Inc. (Berkeley, CA) |
Application Number: | 15/160,729 |
Patent Claims: | see list of patent claims |
Details for Patent 9,814,714
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2035-05-22 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2035-05-22 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2035-05-22 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2035-05-22 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |